1,796 material Form 8-K filings that 1,448 companies we cover made with the SEC in May 2026, each read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). All of them were written later, when past filings were added: a selection, not every 8-K of the month (see the note below).
Dana reported first-quarter 2026 results in an 8-K furnished with Exhibit 99.1. Net sales rose to $1,868 million from $1,781 million, and adjusted EBITDA rose to $171 million from $93 million. Reported net income attributable to the parent company was $1,087 million, or $9.89 per diluted share, driven mainly by $1,106 million of income from discontinued operations, while the net loss from continuing operations narrowed to $15 million.
Net sales of $1,868 million for the three months ended March 31, 2026, versus $1,781 million a year earlier
Adjusted EBITDA of $171 million versus $93 million; Light Vehicle $112 million and Commercial Vehicle $63 million
Diluted adjusted EPS of $0.14 versus a loss of $0.27; GAAP diluted EPS of $9.89 versus $0.17, including $1,106 million from discontinued operations
Adjusted free cash flow was negative $195 million, compared with negative $101 million a year earlier
Binah Capital Group reported first-quarter 2026 results, with GAAP net income rising 84% to $1.9 million and diluted EPS of $0.09, up from $0.04, while total revenue was roughly flat at $48.7 million versus $48.9 million. The company said advisory and brokerage assets grew 12.9% year over year to $29.0 billion, and it promoted Christopher Motta to President of World Equity Group, a subsidiary.
GAAP net income of $1.9 million, up from $1.0 million in Q1 2025
Total revenue of $48.7 million, compared with $48.9 million a year earlier
Diluted EPS of $0.09, compared with $0.04 in the prior-year quarter
Assets under management reached $29.0 billion as of March 31, 2026, up 12.9% year over year
RBC Bearings reported fourth quarter fiscal 2026 net sales of $518.0 million, up 18.3% from a year earlier, with GAAP net income of $91.7 million and GAAP diluted EPS of $2.89, up from $2.30. For the full fiscal year, net sales rose 14.3% to $1,870.9 million and GAAP diluted EPS was $9.09, compared with $7.70. The company expects first quarter fiscal 2027 net sales of $500.0 million to $510.0 million, growth of 14.7% to 17.0%.
Fourth quarter net sales of $518.0 million, up 18.3%; Aerospace & Defense up 41.2%, Industrial up 5.5%
Fourth quarter GAAP net income of $91.7 million vs $72.7 million; diluted EPS of $2.89 vs $2.30
Fiscal 2026 net sales of $1,870.9 million, up 14.3%; GAAP diluted EPS of $9.09 vs $7.70
First quarter fiscal 2027 net sales expected at $500.0 million to $510.0 million; backlog $2.3 billion as of March 28, 2026
Where Food Comes From reported first-quarter 2026 results for the three months ended March 31, 2026, showing total revenue of $5.4 million, up from $5.3 million, and net income of $92,000, or $0.02 per diluted share, up from $31,000 or $0.01 a year earlier. Gross margin fell to 39% from 42%, while the company bought back 24,469 shares for $293,000 during the quarter.
Total revenue rose to $5.4 million from $5.3 million; verification and certification revenue rose to $4.4 million from $4.2 million.
Net income was $92,000, or $0.02 per diluted share, versus $31,000, or $0.01, in the prior-year quarter.
Gross margin was 39% versus 42%, which the company attributed to higher insurance and personnel costs.
Professional services revenue fell to $228,000 from $389,000; the company repurchased 24,469 shares for $293,000 in the quarter.
Instil Bio reported a first quarter 2026 net loss of $4.2 million, or $0.62 per share, compared with a net loss of $28.2 million, or $4.32 per share, a year earlier. The company also said it is evaluating potential acquisitions and in-licensing deals, though it gave no assurance any transaction will occur.
Q1 2026 net loss was $4.2 million ($0.62 per share) versus $28.2 million ($4.32 per share) in Q1 2025.
Research and development expenses fell to $0.7 million from $5.4 million, and restructuring and impairment charges fell to $1.0 million from $16.1 million.
Cash, cash equivalents, restricted cash and marketable securities totaled $74.7 million at March 31, 2026, down from $76.3 million at December 31, 2025, and are expected to fund the current operating plan beyond 2027.
MiNK Therapeutics reported first quarter 2026 results on May 15, 2026. The net loss was about $2.7 million, or $0.57 per share, compared with about $2.8 million, or $0.70 per share, in the same period of 2025. Cash and cash equivalents fell to about $9.5 million from about $13.4 million at December 31, 2025, after the company repaid about $5.2 million on the Agenus convertible note.
Net loss of about $2.7 million, or $0.57 per share, for the quarter ended March 31, 2026, versus about $2.8 million, or $0.70 per share, a year earlier
Cash and cash equivalents of about $9.5 million at March 31, 2026, versus about $13.4 million at December 31, 2025
Repaid about $5.2 million on the Agenus convertible note; raised about $3.0 million through its at-the-market sales agreement in the quarter
Randomized Phase 2 trial of agenT-797 initiated, with preliminary data expected in the second half of 2026; ATS presentation scheduled for May 20, 2026
Galectin Therapeutics reported a first-quarter 2026 net loss applicable to common stockholders of $5.1 million, or $0.08 per share, down from $9.6 million, or $0.15 per share, a year earlier, mainly because research and development expenses fell to $2.2 million from $6.5 million. The company had $14.1 million of cash at March 31, 2026, plus $10 million left on a credit line from its chairman, and said this covers planned operations through May 2027, but its stockholders' deficit widened to $132.0 million.
Net loss applicable to common stockholders was $5.1 million ($0.08 per share) for the quarter ended March 31, 2026, versus $9.6 million ($0.15 per share) a year earlier.
Research and development expenses were $2.2 million, down from $6.5 million, which the company attributed mainly to timing of NAVIGATE trial expenditures.
Cash and cash equivalents were $14.1 million at March 31, 2026, with $10 million remaining under a line of credit from the chairman of the board.
Data from the NAVIGATE trial will be presented at EASL in May 2026, and an in-person Type-C meeting with the FDA is planned for the second quarter.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Briefs marked “Written later” were written in November 2026 for filings that were by then more than three weeks old, so months before mid-October 2026 hold a selection: every material 8-K of the past year for the 100 largest companies we cover and the last 15 important 8-Ks of every other one. Briefs the number check holds back are not shown or counted. Also: the last 45 days, briefs by company, A–Z and the live SEC filings wire.